Autolus Therapeutics Plc · NASDAQ:AUTL
Autolus Therapeutics — Q4 2024 Earnings Presentation
17 slides from Autolus Therapeutics's earnings presentation, Mar 20, 2025
Slide 1: Q4 2024 Financial Results and Business Updates
Q4 2024 Financial Results and Business Updates 20 March 2025 Autolus.com For Investor communication only. Not for use in product promotion. Not for further distribution. Exhibit 99.2
Slide 2: Disclaimer
Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,”
Slide 3: Agenda
Agenda 3 • Welcome and Introduction: Amanda Cray, ED, Investor Relations & External Communications • Operational Highlights: Dr. Christian Itin, CEO • Financial Results: Rob Dolski, CFO • Upcoming Milestones and Conclusion: Dr. Christian Itin, CEO • Q&A: Dr. Christian Itin and Rob Dolski
Slide 4: 2025 Key Objectives
2025 Key Objectives 4 Execution in 2024 set us up to achieve objectives Execute Launch Drive growth • Execute on successful commercial launch of AUCATZYL® both in the U.S. and expanding into new markets • Establish the next wave of investments to expand the obe-cel opportunity, advance our clinical
Slide 5: Autolus executed to plan in 2024
Autolus executed to plan in 2024 5 Focused on commercial launch and pipeline opportunities in 2025 AUCATZYL US launch Obe-cel in r/r adult B-ALL • AUCATZYL approved by the FDA for the treatment of adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia on November 8, 2024 ($3
Slide 6: FELIX trial published in New England Journal of Medicine
FELIX trial published in New England Journal of Medicine1 6 Favourable response rate and tolerability, despite challenging patient population 1. Roddie C, et al "Obecabtagene autoleucel in B-cell acute lymphoblastic leukemia" N Engl J Med 2024; DOI: 10.1056/NEJMoa2406526 High overall response rate w
Slide 7: Deep molecular responses result in long term remissions in adult ALL
Deep molecular responses result in long term remissions in adult ALL Survival outcomes show potential of long-term plateau with 12-month EFS rates 49.5% • In all patients, the median EFS was 11.9 months • Lower disease burden at lymphodepletion was associated with better outcomes 1. Roddie C, et al
Slide 8: Deep molecular responses result in long term remissions in adult ALL
Deep molecular responses result in long term remissions in adult ALL • In all patients, the median OFS was 15.6 months • Lower disease burden at lymphodepletion was associated with better outcomes 1. Roddie C, et al "Obecabtagene autoleucel in B-cell acute lymphoblastic leukemia" N Engl J Med 2024;
Slide 9: Early Momentum in the AUCATZYL Launch
Early Momentum in the AUCATZYL® Launch 9 33 Treatment Centers Authorized as of 3/19/25 Patient Access is on Track https://www.autolusassist.com/find-a-treatment-center/ • 30 centers covering 60% of target population completed ahead of plan • End of 2025 target: ~60 centers covering 90% of population
Slide 10: Expanding the obe-cel opportunity
Expanding the obe-cel opportunity Deep value program with potentially broad applicability
Slide 11: Growth drivers for obe-cel
11 Growth drivers for obe-cel Updates to be provided at R&D event in New York, April 23, 2025 Autoimmune Hem-oncology Early pipeline • Phase 1 dose confirmation study (CARLYSLE) in SLE ongoing • All six patients dosed • Initial data to be presented at R&D event on April 23, 2025 • H2 2025 for presen
Slide 12: The obe-cel product family and franchise opportunity
The obe-cel product family and franchise opportunity 12 Obe-cel CD19 AUTO1/22 CD19/CD22 AUTO8 CD19/BCMA B-ALL and B-NHL B-cell mediated autoimmune disease B-ALL and B-NHL Multiple Myeloma B-cell and plasma cell mediated autoimmune • Optimized CD19 CAR design • Potential best-in-class efficacy and sa
Slide 13: Financial Results
Financial Results
Slide 14: Financial summary – Key Metrics
Financial summary – Key Metrics* USD ($’ 000) FY 2024 FY 2023 Variance Cash, cash equivalents and marketable securities 588,023 239,566 348,457 Total revenue, net 10,120 1,698 8,422 Cost and operating expenses: Cost of sales (11,387) - (11,387) Research and development expenses, net (138,436) (130,4
Slide 15: Upcoming news flow
Upcoming news flow
Slide 16: Autolus news flow
Autolus news flow 16 Anticipated Milestone or Catalyst Anticipated Timing Initial data from SLE Phase 1 trial April 23 Company R&D event, New York April 23 Initial data from PY01 trial in pediatric ALL H2 2025 Notification from UK and EU regarding approval in ALL H2 2025 SLE Phase 1 trial presentati
Slide 17: Thank you
Autolus.com Thank you